Exploring the “Other” subfamily of HECT E3-ligases for therapeutic intervention

• Published in: Pharmacology & therapeutics (Oxford) Vol. 224; p. 107809
• Main Authors: Singh, Sunil, Ng, Joel, Sivaraman, J.
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01-08-2021
• Subjects: Cancer; E3 ubiquitin ligase; Humans; Posttranslational modification; Protein Degradation; Ubiquitin-Protein Ligases - pharmacology; Ubiquitination; “Other” subfamily HECT; DYRK2; UBE3C; BAF57; UBE3B; PIPKIγ90; AZUL; HECT; Ubiquitination; RING; E6AP; USP7; AREL1; RBR; MNF2; Ub; PIAS1; G2E3; E3 ubiquitin ligase; IRF; ANK; OPTN; pRb; PTM; kDa; IQGAP1; MALT1; HPV; PDB; Posttranslational modification; SOCS2; HECTD1; HECTD2; NRF2; HECTD3; KSHV; HECTD4; UBR5; NF- κB; Protein Degradation; HSP90; HACE1; FIH; HUWE1; β₂AR; “Other” subfamily HECT; BCKDK; NEDD4; TRIP12; Cancer
• ISSN: 0163-7258; 1879-016X
• DOI: 10.1016/j.pharmthera.2021.107809

The HECT E3 ligase family regulates key cellular signaling pathways, with its 28 members divided into three subfamilies: NEDD4 subfamily (9 members), HERC subfamily (6 members) and “Other” subfamily (13 members). Here, we focus on the less-explored “Other” subfamily and discuss the recent findings pertaining to their biological roles. The N-terminal regions preceding the conserved HECT domains are significantly diverse in length and sequence composition, and are mostly unstructured, except for short regions that incorporate known substrate-binding domains. In some of the better-characterized “Other” members (e.g., HUWE1, AREL1 and UBE3C), structure analysis shows that the extended region (~ aa 50) adjacent to the HECT domain affects the stability and activity of the protein. The enzymatic activity is also influenced by interactions with different adaptor proteins and inter/intramolecular interactions. Primarily, the “Other” subfamily members assemble atypical ubiquitin linkages, with some cooperating with E3 ligases from the other subfamilies to form branched ubiquitin chains on substrates. Viruses and pathogenic bacteria target and hijack the activities of “Other” subfamily members to evade host immune responses and cause diseases. As such, these HECT E3 ligases have emerged as potential candidates for therapeutic drug development.